Literature DB >> 17479939

Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.

Aurelio Barricarte1, Jesús Castilla, Alberto Gil-Setas, Luis Torroba, José Antonio Navarro-Alonso, Fátima Irisarri, Maite Arriazu.   

Abstract

BACKGROUND: The 7-valent pneumococcal conjugate vaccine (PCV7) has shown high efficacy in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. We aimed to assess the overall effectiveness of PCV7 against IPD in Navarra, Spain.
METHODS: All children aged <5 years who were diagnosed with IPD during the period 2001-2005 (n=85) and 5 control subjects per case patient (n=425), individually matched by birth date and birth hospital, were analyzed. Vaccination records were obtained from the regional immunization registry. Conditional logistic regression was used to estimate odds ratios.
RESULTS: Eighteen case patients (21%) and 114 control subjects (27%) had received >or=1 dose of PCV7. PCV7 serotypes were responsible for 34 (51%) of the cases in unvaccinated children. The overall effectiveness for case prevention was 31% (odds ratio, 0.69; 95% confidence interval, 0.37-1.27). In a separate analysis, vaccination with PCV7 was 88% effective in preventing IPD due to vaccine serotypes (odds ratio, 0.12; 95% confidence interval, 0.02-0.91) and was associated with a higher risk of IPD due to nonvaccine serogroups (odds ratio, 6.16; 95% confidence interval, 1.63-23.3).
CONCLUSIONS: These data reveal a higher risk of IPD caused by non-PCV7 serogroups among vaccinated children. Consequently, the overall effectiveness of PCV7 for IPD prevention may be greatly reduced.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17479939     DOI: 10.1086/516779

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Population structure of invasive Streptococcus pneumoniae isolates in Italy prior to the implementation of the 7-valent conjugate vaccine (1999-2003).

Authors:  G Gherardi; F D'Ambrosio; M Monaco; R Camilli; L De Florio; F D'Ancona; G Dicuonzo; A Pantosti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-29       Impact factor: 3.267

2.  Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  E Pérez-Trallero; J M Marimon; M Ercibengoa; D Vicente; E G Pérez-Yarza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-20       Impact factor: 3.267

3.  Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales.

Authors:  Nick Andrews; Pauline A Waight; Ray Borrow; Shamez Ladhani; Robert C George; Mary P E Slack; Elizabeth Miller
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

4.  Pneumococcal serotypes in children in 4 European countries.

Authors:  Germaine Hanquet; Esther Kissling; Asuncion Fenoll; Robert George; Agnes Lepoutre; Tinne Lernout; David Tarragó; Emmanuelle Varon; Jan Verhaegen
Journal:  Emerg Infect Dis       Date:  2010-09       Impact factor: 6.883

Review 5.  Impact of pneumococcal conjugate vaccination on otitis media: a systematic review.

Authors:  Sylvia Taylor; Paola Marchisio; Anne Vergison; Julie Harriague; William P Hausdorff; Mark Haggard
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

Review 6.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.

Authors:  Laura Conklin; Jennifer D Loo; Jennifer Kirk; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 7.  Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Authors:  A Torres; P Bonanni; W Hryniewicz; M Moutschen; R R Reinert; T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-23       Impact factor: 3.267

8.  Pediatric parapneumonic empyema, Spain.

Authors:  Ignacio Obando; Carmen Muñoz-Almagro; Luis A Arroyo; David Tarrago; David Sanchez-Tatay; David Moreno-Perez; Sahar S Dhillon; Cristina Esteva; Susanna Hernandez-Bou; Juan J Garcia-Garcia; William P Hausdorff; Angela B Brueggemann
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

9.  How is vaccine effectiveness scaled by the transmission dynamics of interacting pathogen strains with cross-protective immunity?

Authors:  Ryosuke Omori; Benjamin J Cowling; Hiroshi Nishiura
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Diversity of pneumococcal surface protein A (PspA) among prevalent clones in Spain.

Authors:  Dora Rolo; Carmen Ardanuy; Ana Fleites; Rogelio Martín; Josefina Liñares
Journal:  BMC Microbiol       Date:  2009-05-06       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.